Pulnovo Medical Highlights Global Clinical Exposure for PADN Technology at INDIALIVE2026

A LinkedIn post from Pulnovo Medical describes PADN technology being featured in a live transmission at the INDIALIVE2026 cardiology meeting in New Delhi. The procedure, led by a team from West China Hospital of Sichuan University, was presented as demonstrating a mature, standardized clinical pathway and showing persuasive improvements in clinical metrics to an international expert audience.

The post indicates that experts discussed PADN’s potential role in optimizing long-term medication management for pulmonary hypertension, with possible implications for lowering treatment costs and improving patient quality of life. Academic sessions from a Cleveland Clinic physician were cited as reinforcing the scientific rationale and use of PADN in complex, high-risk cases, suggesting growing clinical interest that could support Pulnovo Medical’s positioning in interventional therapies for pulmonary hypertension.

From an investor perspective, the post implies increasing global visibility for Pulnovo Medical’s PADN platform through high-profile conference exposure and engagement with recognized international centers. If this visibility translates into broader clinical adoption, regulatory progress, or partnerships, it could enhance the company’s commercialization prospects and strengthen its competitive stance in the medtech segment targeting pulmonary hypertension.

The post also references Pulnovo Medical’s intention to expand its global footprint and collaborate with international authorities on evidence-based solutions. While no specific financial targets, timelines, or geographies are mentioned, this outward-looking strategy may signal continued investment in clinical validation and market development, factors that investors may monitor as indicators of long-term growth potential and capital needs.